1,2,3,4-tetrahydroisoquinolin-7-yl methanol | 220247-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1,2,3,4-tetrahydroisoquinolin-7-yl methanol
• 英文别名: (1,2,3,4-Tetrahydroisoquinolin-7-yl)methanol；1,2,3,4-tetrahydroisoquinolin-7-ylmethanol
• CAS: 220247-51-8
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: RAUHFTOXJZRVIJ-UHFFFAOYSA-N

物化性质

• 沸点：
  323.6±37.0 °C(Predicted)
• 密度：
  1.117±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,2,3,4-四氢异喹啉-7-甲腈 在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 30.0h， 生成 1,2,3,4-tetrahydroisoquinolin-7-yl methanol
  参考文献：
  名称：

  Synthesis, Biochemical Evaluation, and Classical and Three-Dimensional Quantitative Structure−Activity Relationship Studies of 7-Substituted-1,2,3,4-tetrahydroisoquinolines and Their Relative Affinities toward Phenylethanolamine N-Methyltransferase and the α₂-Adrenoceptor^,1

  摘要：

  7-Substituted-1,2,3,4-tetrahydroisoquinolines (7-substituted-THIQs) are potent inhibitors of phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28), the enzyme involved in the biosynthesis of epinephrine. Unfortunately, most of these compounds also exhibit strong affinity for the aa-adrenoceptor. To design a selective (PNMT vs alpha(2)-adrenoceptor affinity) inhibitor of PNMT, the steric and electrostatic factors responsible for PNMT inhibitory activity and alpha(2)-adrenoceptor affinity were investigated by evaluating a number of 7-substituted-THIQs. A classical quantitative structure-activity relationship (QSAR) study resulted in a three-parameter equation for PNMT (PNMT pK(i) = 0.599 pi - 0.0725MR + 1.55 sigma(m) + 5.80; n = 27, r = 0.885, s = 0.573) and a three-parameter equation for the alpha(2)-adrenoceptor (alpha(2) pK(i) = 0.599 pi - 0.0542MR - 0.951 sigma(m) + 6.45; n = 27, r = 0.917, s = 0.397). These equations indicated that steric effects and lipophilicity play a similar role at either active site but that electronic effects play opposite roles at either active site. Two binding orientations for the THIQs were postulated such that lipophilic and hydrophilic 7-substituents would not occupy the same region of space at either binding site. Using these two binding orientations, based on the lipophilicity of the 7-substituent, comparative molecular field analysis (CoMFA) models were developed that showed that the steric and electrostatic interactions at both sites were similar to those previously elaborated in the QSAR analyses. Both the QSAR and the CoMFA analyses showed that the steric interactions are similar at the PNMT active site and at the alpha(2)-adrenoceptor and that the electrostatic interactions were different at the two sites. This difference in electrostatic interactions might be responsible for the selectivity of THIQs bearing a nonlipophilic electron-withdrawing group at the 7-position, These QSAR and CoMFA results will be useful in the design of potent and selective (PNMT vs alpha(2)-adrenoceptor affinity) inhibitors of PNMT.

  DOI：

  10.1021/jm980429p

文献信息

• METHODS AND COMPOUNDS FOR INHIBITING AMYLOID DEPOSITS
  申请人：Szarek Walter A.

  公开号：US20080227767A1

  公开（公告）日：2008-09-18

  Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

  本发明提供了在治疗淀粉样变性方面有用的方法和组合物。具体而言，提供了用于抑制、预防和治疗淀粉样沉积的方法和组合物，例如在胰岛中，其中淀粉样沉积是胰岛淀粉样多肽(IAPP)相关的淀粉样沉积或沉积物。本发明的方法涉及向受试者施用抑制IAPP相关淀粉样沉积的治疗化合物。因此，本发明的组合物和方法对于抑制IAPP相关淀粉样变性在发生此类淀粉样沉积的疾病，如糖尿病方面是有用的。
• PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：EP3666766A1

  公开（公告）日：2020-06-17

  The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

  本发明提供了一种由下式[I]代表的化合物或其药学上可接受的盐，对 20-HETE 生成酶具有抑制作用。 (上式[I]中，下式[II]所代表的结构： 代表下式组[III]所代表的任何一种结构： R1、R2、R3 和 R4 独立地代表氢原子、氟原子、甲基或类似物、 R5 代表式组 [IV] 所代表的任何一种结构：
• Pyridine compound substituted with azole
  申请人：TAISHO PHARMACEUTICAL CO., LTD.

  公开号：US11365192B2

  公开（公告）日：2022-06-21

  The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

  本发明提供了一种由下式[I]代表的化合物或其药学上可接受的盐，对 20-HETE 生成酶具有抑制作用。 (上式[I]中，下式[II]所代表的结构： 代表下文式组 [III] 所代表的任何一种结构： R1、R2、R3 和 R4 独立地代表氢原子、氟原子、甲基或类似物，R5 代表式组 [IV] 所代表的任何结构：
• EP3666766
  申请人：——

  公开号：——

  公开（公告）日：——
• COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS
  申请人：BELLUS Health (International) Limited

  公开号：EP1227803B1

  公开（公告）日：2010-05-05